Clinical study results in the low-to-mid teens across a range of patients1
XEN® achieved mean intraocular pressure (IOP) of 15.9 (+ 5.2) mm Hg baseline medicated IOP of 25.1 (+ 3.7) mm Hg through 12 months (n = 52).1
The first ab interno approach to create a new pathway for aqueous outflow1
Versatility that could help more of your indicated refractory glaucoma patients get into the XEN® Zone1
Established efficacy and safety1
DESIGNED FOR EFFICACY
XEN® is the only FDA-cleared stent that creates a low-lying, ab interno bleb for effective IOP reduction1
Redirect Your ThinkingCLINICAL VERSATILITY
XEN® is appropriate for refractory open-angle glaucoma patients, including those who are1:
- Pseudophakic
- Uncontrolled on maximum tolerated medical therapy
- Inadequately controlled by prior surgery, including MIGS and SLT*
- Undergoing cataract surgery or a stand-alone procedure
DOCUMENTED XEN® OUTCOMES
In the primary analysis at 12 months, 76.3% (95% CI = 65.8, 86.8%) of subjects achieved ≥ 20% mean diurnal IOP reduction on the same or fewer number of medications vs baseline (N = 65).1
See the Data